Nevertheless, it is advisable to assess bone metabolism anomalies, especially in children with the PTPN11 pathogenic variant, before administering the medication as well as to monitor scoliosis and osteochondroma during their post‐treatment phase. Here, PTPN11 is linked to scoliosis.